Literature DB >> 20473134

Subtypes of mild cognitive impairment in older postmenopausal women: the Women's Health Initiative Memory Study.

Stephen R Rapp1, Claudine Legault, Victor W Henderson, Robert L Brunner, Kamal Masaki, Beverly Jones, John Absher, Leon Thal.   

Abstract

Mild cognitive impairment (MCI) is a transitional state between normal cognitive functioning and dementia. A proposed MCI typology classifies individuals by the type and extent of cognitive impairment, yet few studies have characterized or compared these subtypes. Four hundred forty-seven women 65 years of age and older from the Women's Health Initiative Memory Study were classified into the 4 MCI subgroups and a "no impairment" group and compared on clinical, sociodemographic, and health variables. A cognitive deficit in at least 1 domain was present in 82.1% of participants, with most (74.3%) having deficits in multiple cognitive domains. Only 4.3% had an isolated memory deficit, whereas 21.3% had an isolated nonmemory deficit. Of the 112 women who met all MCI criteria examined, the most common subtype was amnestic multidomain MCI (42.8%), followed by nonamnestic multiple domain MCI (26.7%), nonamnestic single domain (24.1%), and amnestic single domain MCI (6.3%). Subtypes were similar with respect to education, health status, smoking, depression, and prestudy and onstudy use of hormone therapy. Despite the attention it receives in the literature, amnestic MCI is the least common type highlighting the importance of identifying and characterizing other nonamnestic and multidomain subtypes. Further research is needed on the epidemiology of MCI subtypes, clinical and biologic differences between them, and rates for conversion to dementia.

Entities:  

Mesh:

Year:  2010        PMID: 20473134      PMCID: PMC2929315          DOI: 10.1097/WAD.0b013e3181d715d5

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  39 in total

Review 1.  What is cognitive reserve? Theory and research application of the reserve concept.

Authors:  Yaakov Stern
Journal:  J Int Neuropsychol Soc       Date:  2002-03       Impact factor: 2.892

2.  Dementia diagnoses from clinical and neuropsychological data compared: the Cache County study.

Authors:  J T Tschanz; K A Welsh-Bohmer; I Skoog; N West; M C Norton; B W Wyse; R Nickles; J C Breitner
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910

Review 3.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

Review 4.  Cognitive impairment with no dementia (CIND): longitudinal studies, the findings, and the issues.

Authors:  H Tuokko; R J Frerichs
Journal:  Clin Neuropsychol       Date:  2000-11       Impact factor: 3.535

5.  Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R C Petersen; J C Stevens; M Ganguli; E G Tangalos; J L Cummings; S T DeKosky
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

6.  Natural history of mild cognitive impairment in older persons.

Authors:  D A Bennett; R S Wilson; J A Schneider; D A Evans; L A Beckett; N T Aggarwal; L L Barnes; J H Fox; J Bach
Journal:  Neurology       Date:  2002-07-23       Impact factor: 9.910

7.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Stephen R Rapp; Mark A Espeland; Sally A Shumaker; Victor W Henderson; Robert L Brunner; JoAnn E Manson; Margery L S Gass; Marcia L Stefanick; Dorothy S Lane; Jennifer Hays; Karen C Johnson; Laura H Coker; Maggie Dailey; Deborah Bowen
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

8.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Evaluation of dementia in the cardiovascular health cognition study.

Authors:  Oscar L Lopez; Lewis H Kuller; Annette Fitzpatrick; Diane Ives; James T Becker; Norman Beauchamp
Journal:  Neuroepidemiology       Date:  2003 Jan-Feb       Impact factor: 3.282

10.  Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease.

Authors:  G A Jicha; F A Schmitt; E Abner; P T Nelson; G E Cooper; C D Smith; W R Markesbery
Journal:  Neurobiol Aging       Date:  2008-11-20       Impact factor: 4.673

View more
  12 in total

Review 1.  Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on.

Authors:  P M Maki; V W Henderson
Journal:  Climacteric       Date:  2012-06       Impact factor: 3.005

2.  Mild cognitive impairment in long-term brain tumor survivors following brain irradiation.

Authors:  Christina K Cramer; Neil McKee; L Doug Case; Michael D Chan; Tiffany L Cummings; Glenn J Lesser; Edward G Shaw; Stephen R Rapp
Journal:  J Neurooncol       Date:  2018-11-07       Impact factor: 4.130

3.  Effects of varying diagnostic criteria on prevalence of mild cognitive impairment in a community based sample.

Authors:  Emily H Trittschuh; Paul K Crane; Eric B Larson; Brenna Cholerton; Wayne C McCormick; Susan M McCurry; James D Bowen; Laura D Baker; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  Mild cognitive impairment, dementia, and their subtypes in oldest old women.

Authors:  Kristine Yaffe; Laura E Middleton; Li-Yung Lui; Adam P Spira; Katie Stone; Caroline Racine; Kristine E Ensrud; Joel H Kramer
Journal:  Arch Neurol       Date:  2011-05

Review 5.  The relation between thyroid dysregulation and impaired cognition/behaviour: An integrative review.

Authors:  Manizhe Eslami-Amirabadi; Seyed Ahmad Sajjadi
Journal:  J Neuroendocrinol       Date:  2021-03       Impact factor: 3.627

6.  Prevalence, distribution, and impact of mild cognitive impairment in Latin America, China, and India: a 10/66 population-based study.

Authors:  Ana Luisa Sosa; Emiliano Albanese; Blossom C M Stephan; Michael Dewey; Daisy Acosta; Cleusa P Ferri; Mariella Guerra; Yueqin Huang; K S Jacob; Ivonne Z Jiménez-Velázquez; Juan J Llibre Rodriguez; Aquiles Salas; Joseph Williams; Isaac Acosta; Maribella González-Viruet; Milagros A Guerra Hernandez; Li Shuran; Martin J Prince; Robert Stewart
Journal:  PLoS Med       Date:  2012-02-07       Impact factor: 11.069

7.  Interaction between C-reactive protein and cognitive functions according to APOE gene polymorphism in post-menopausal women.

Authors:  Iwona Bojar; Mariusz Gujski; Jarosław Pinkas; Dorota Raczkiewicz; Alfred Owoc; Ewa Humeniuk
Journal:  Arch Med Sci       Date:  2016-10-24       Impact factor: 3.318

8.  The effect of hormone replacement therapy on cognitive function in postmenopausal women: An RCT.

Authors:  Fereshteh Moradi; Shahideh Jahanian Sadatmahalleh; Saeideh Ziaei
Journal:  Int J Reprod Biomed       Date:  2019-01-28

9.  Does genetic testing for ERα gene polymorphisms provide new possibilities of treatment for cognitive function disorders in postmenopausal women?

Authors:  Mariusz Gujski; Jarosław Pinkas; Anna Wierzbińska-Stępniak; Alfred Owoc; Iwona Bojar
Journal:  Arch Med Sci       Date:  2016-09-22       Impact factor: 3.318

10.  A prospective cohort study investigating contributors to mild cognitive impairment in adults with spinal cord injury: study protocol.

Authors:  Danielle Sandalic; Ashley Craig; Mohit Arora; Ilaria Pozzato; Grahame Simpson; Bamini Gopinath; Jasbeer Kaur; Sachin Shetty; Gerard Weber; Ian Cameron; Yvonne Tran; James Middleton
Journal:  BMC Neurol       Date:  2020-09-11       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.